Pharvaris (Nasdaq: PHVS) announced the publication of results from two Phase 2 clinical trials for its lead drug candidate, deucrictibant, in the prestigious medical journal The Lancet Haematology. The CHAPTER-1 and RAPIDe-1 studies demonstrated the efficacy and safety of the drug for both the prophylaxis and on-demand treatment of Hereditary Angioedema (HAE) attacks. Deucrictibant is an oral small-molecule bradykinin B2 receptor antagonist designed to offer a more convenient and effective treatment option for patients. This peer-reviewed publication validates the drug's clinical potential, marking a significant scientific milestone for the company's development program. Following the announcement, investor confidence in the drug's path toward regulatory approval is expected to strengthen within the biotech sector. Pharvaris continues to advance its clinical pipeline as it seeks to address critical unmet needs in the global HAE market.
Sign up free to access this content
Create Free Account